List view / Grid view
Complex diseases rarely have single targets. By focusing on transcription factor activity and disease signatures, Scripta Therapeutics is taking a different approach to identifying the drivers of pathology.
AI is moving from a supporting role into the core of drug discovery. By 2026, it is expected to shape how targets are chosen, how biology is analysed and how development decisions are made.
Drug-induced liver injury remains one of drug development’s most costly pitfalls. Now, AI and transcriptomics may offer a way to spot risks long before they reach patients.
Stress during pregnancy may disrupt the maternal gut-immune system, altering foetal brain development and revealing sex-specific vulnerabilities linked to neurodevelopmental risk
A new study suggests that a low-cost form of non-invasive prenatal screening could help clinicians identify pregnant women at highest risk of transmitting cytomegalovirus to their babies.
Seattle-based biotech company, Variant Bio, have launched Inference, an AI-powered genomics platform designed to accelerate drug discovery and identify genetically supported targets.
Procedural advances in IVF are reaching their biological limits. Reproductive biotech is now moving upstream, developing first in class therapeutics that target meiosis, gamete quality and implantation biology as druggable mechanisms in early discovery.
The DMTA cycle depends on clear data flow, yet most labs still work across disconnected systems. Sean McGee, Director of Product at Certara, explains how better infrastructure and AI can help teams work faster and make decisions with more confidence.
Scientists have developed an experimental RNA-based drug, TY1, that repairs DNA, reduces scar tissue and could lead to new treatments for heart attacks and autoimmune diseases.
Every great leap in history started with a single, urgent need. Now AI is emerging as the next great engine of invention, transforming the future of medicine faster than ever imagined.
Researchers have discovered how renal medullary carcinoma cells evade immunotherapy by mimicking immune cells, driving rapid tumour progression.
Find out how a three-dimensional view of the genome is giving scientists a clearer picture of disease biology and revealing new opportunities for targeted therapies.
New research has shown that the enzyme OTULIN regulates tau at the gene-expression level rather than through protein degradation.
Bigger isn’t always better. In drug discovery, Dr Michael Ritchie argues that the future belongs not to those with the most data, but to those who understand its biological depth.
At ELRIG’s Drug Discovery 2025, Drug Target Review spoke with the teams turning big ideas into usable tools – automation, AI and biology – that help scientists work smarter.
